Patents by Inventor Jeffrey T. McGrew
Jeffrey T. McGrew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240035037Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence or a human cytomegalovirus (huCMV) intron A sequence. Some of the vectors are useful for inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and methods of producing a protein of interest, in vitro, involving the mammalian host cell.Type: ApplicationFiled: July 3, 2023Publication date: February 1, 2024Applicant: Just-Evotec Biologics, Inc.Inventors: Jeffrey T. McGrew, James Joyce McDermott, Sherman Ku
-
Patent number: 11692193Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.Type: GrantFiled: March 3, 2021Date of Patent: July 4, 2023Assignee: Just-Evotec Biologies, Inc.Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
-
Patent number: 11685933Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.Type: GrantFiled: February 1, 2022Date of Patent: June 27, 2023Assignee: Just-Evotec Biologics, Inc.Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
-
Patent number: 11384140Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.Type: GrantFiled: May 11, 2017Date of Patent: July 12, 2022Assignee: Amgen Inc.Inventors: Randal Robert Ketchem, Jeffrey T. McGrew, Dina A. Fomina Yadlin
-
Publication number: 20220177916Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.Type: ApplicationFiled: February 1, 2022Publication date: June 9, 2022Applicant: Just-Evotec Biologics, Inc.Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
-
Patent number: 11261462Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.Type: GrantFiled: February 26, 2019Date of Patent: March 1, 2022Assignee: Just-Evotec Biologics, Inc.Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
-
Patent number: 11098310Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.Type: GrantFiled: February 26, 2019Date of Patent: August 24, 2021Assignee: JUST-EVOTEC BIOLOGICS, INC.Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
-
Publication number: 20210189403Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.Type: ApplicationFiled: March 3, 2021Publication date: June 24, 2021Applicant: Just-Evotec Biologics, IncInventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
-
Patent number: 11028410Abstract: A hybrid promoter for recombinant expression of proteins of interest is disclosed that combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Also disclosed are an expression cassette containing the hybrid promoter and a recombinant expression vector containing the expression cassette. A mammalian host cell, which comprises the recombinant expression vector is also disclosed, as is a method of producing a protein of interest that employs the mammalian host cell, optionally involving tetracycline-inducible expression of the protein.Type: GrantFiled: January 26, 2017Date of Patent: June 8, 2021Assignee: JUST-EVOTEC BIOLOGICS, INC.Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
-
Publication number: 20190185863Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.Type: ApplicationFiled: February 26, 2019Publication date: June 20, 2019Applicant: Just Biotherapeutics, Inc.Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
-
Publication number: 20190185881Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.Type: ApplicationFiled: February 26, 2019Publication date: June 20, 2019Applicant: Just Biotherapeutics, Inc.Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
-
Publication number: 20190127452Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.Type: ApplicationFiled: May 11, 2017Publication date: May 2, 2019Applicant: AMGEN INC.Inventors: Randal Robert KETCHEM, Jeffrey T. MCGREW, Dina A. FOMINA YADLIN, Trent P. MUNRO, Neeraj Jagdish AGRAWAL, Kristine M. DARIS
-
Publication number: 20190055580Abstract: A hybrid promoter for recombinant expression of proteins of interest is disclosed that combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Also disclosed are an expression cassette containing the hybrid promoter and a recombinant expression vector containing the expression cassette. A mammalian host cell, which comprises the recombinant expression vector is also disclosed, as is a method of producing a protein of interest that employs the mammalian host cell, optionally involving tetracycline-inducible expression of the protein.Type: ApplicationFiled: January 26, 2017Publication date: February 21, 2019Applicant: Just Biotherapeutics, Inc.Inventors: Jeffrey T. McGrew, Pauline S. Smitdt, E-Ching Ong
-
Publication number: 20140093915Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.Type: ApplicationFiled: September 3, 2013Publication date: April 3, 2014Applicant: AMGEN INC.Inventors: DIRK E. SMITH, JOHN E. SIMS, JEFFREY T. MCGREW, MAREK Z. KUBIN, DUNCAN COCHRANE, LOUISE CONROY
-
Patent number: 8540993Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.Type: GrantFiled: August 20, 2012Date of Patent: September 24, 2013Assignee: AMGEN Inc.Inventors: Dirk E. Smith, John E. Sims, Jeffrey T. McGrew, Marek Z. Kubin, Duncan Cochrane, Louise Conroy
-
Publication number: 20130034569Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.Type: ApplicationFiled: August 20, 2012Publication date: February 7, 2013Inventors: Dirk E. SMITH, John E. Sims, Jeffrey T. McGrew, Marek Z. Kubin, Duncan Cochrane, Louise Conroy
-
Patent number: 8257707Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.Type: GrantFiled: July 24, 2008Date of Patent: September 4, 2012Assignee: Amgen Inc.Inventors: Dirk E. Smith, John E. Sims, Jeffrey T. McGrew, Marek Z. Kubin, Duncan Cochrane, Louise Conroy
-
Patent number: 7968313Abstract: This invention is in the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.Type: GrantFiled: November 6, 2009Date of Patent: June 28, 2011Assignee: Amgen Inc.Inventors: Jeffrey T. McGrew, Allison A. Bianchi
-
Publication number: 20110014201Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.Type: ApplicationFiled: July 24, 2008Publication date: January 20, 2011Applicant: AMGEN INC.Inventors: Dirk E. Smith, John E. Sims, Jeffrey T. McGrew, Marek Z. Kubin, Duncan Cochrane, Louise Conroy
-
Patent number: 7691605Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.Type: GrantFiled: September 20, 2002Date of Patent: April 6, 2010Assignee: Immunex CorporationInventors: Jeffrey T. McGrew, Allison A. Bianchi